Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTER-EWING-1 Trial 1 in newly diagnosed Ewing sarcoma
NL-OMON59446Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of regorafenib, vinorelbine and cyclophosphamide in Ewing sarcoma and round cell sarcoma (8 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Started Feb 2026; status: recruiting.
02
Drugs
regorafenibvinorelbinecyclophosphamide
03
Conditions
Ewing sarcomaround cell sarcoma
Beyond the preview
Go deeper on NL-OMON59446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59446.